China Pharma Holdings, Inc.

CPHI Healthcare Drug Manufacturers Specialty & Generic

China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024.

Revenue
−7.56%
EPS
+75.0%
Free cash flow
−113.6%
Total debt
−2.92%

Quarter to June 2026, against a year earlier

0.56 0.03 +5.66%
Market cap
$22.8M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
5/9
Altman Z
−2.16
Beneish M
n/a
Dividend safety
n/a

China Pharma Holdings, Inc. (CPHI) P/E ratio

Alert me on P/E ratio

China Pharma Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
42 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
AYTU Aytu BioPharma, Inc. compare n/m
RMTI Rockwell Medical, Inc. compare n/m
SCYX SCYNEXIS, Inc. compare n/m
TXMD TherapeuticsMD, Inc. compare n/m
SHPH Shuttle Pharmaceuticals Holdings, Inc. compare n/m
IXHL Incannex Healthcare Inc. compare n/m
CPHI China Pharma Holdings, Inc. n/m
INCR InterCure Ltd. compare 6.2×
ZYBT Zhengye Biotechnology Holding Limited compare —
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CPHI